Merck & Co. has speared an acquisition target, agreeing to pay $680 million for Harpoon Therapeutics and its pipeline of T-cell engagers. The deal will give Merck control of drug candidates that will ...
Merck & Co. has quickly recouped some of the costs of its Harpoon Therapeutics buyout, pulling in $170 million upfront by incorporating the lead candidate into a co-development deal with Daiichi ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Curon Biopharmaceutical (Curon), a privately held biotechnology company, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback